Company news

MeiraGTx Holdings plc news in 2024

MeiraGTx Holdings plc's news releases, calls and decks from 2024, newest first.

View company

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

December 8, 2024

MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates

November 12, 2024

MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress

October 21, 2024

MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson’s Disease

October 14, 2024

MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference

October 8, 2024

MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi

August 11, 2024

MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results

August 11, 2024

MeiraGTx Reports First Quarter 2024 Financial and Operational Results

May 8, 2024

MeiraGTx to Participate in Upcoming Investor Conferences

April 23, 2024

MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference

April 17, 2024

MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates

March 13, 2024

MeiraGTx Announces $50 Million Milestone from Janssen Pharmaceuticals

February 12, 2024

Decks in 2024